Nanoparticles that precisely target tumours are here

In a major breakthrough, scientists have designed nanoparticles that can deliver drugs directly to a tumour.
But what makes it special is that those nanoparticles that do not hit their target can be broken down and eliminated easily.
The nanoparticle is encased in a shell coated with a peptide that enables it to target tumour cells.
"The disassembly is an interesting concept for creating drugs that respond to a certain stimulus," said Gary Braun, a post-doctoral associate in the Ruoslahti Lab at University of California, Santa Barbara.
It also minimises the off-target toxicity by breaking down the excess nanoparticles so that they can then be cleared through the kidneys, he added.
The method for removing nanoparticles unable to penetrate target cells is unique.
"By focusing on the nanoparticles that actually got into cells, we can then understand which cells were targeted and study the tissue transport pathways in more detail," Braun explained.
Some drugs are able to pass through the cell membrane on their own, but many drugs, especially RNA and DNA genetic drugs, are charged molecules that are blocked by the membrane.
These drugs must be taken in through endocytosis, the process by which cells absorb molecules by engulfing them.
"This typically requires a nanoparticle carrier to protect the drug and carry it into the cell," Braun noted.
"And that is what we measured - the internalisation of a carrier via endocytosis," he said.
Because the nanoparticle has a core shell structure, the researchers can vary its exterior coating and compare the efficiency of tumour targeting and internalisation.
The findings appeared in the journal Nature Materials.

depresson-problem is going to be solved in the days to come.


Tiny molecule will end trial and error era for depression treatment

BY | June 9, 2014
Tiny molecule will help find right medication for depression. The trial and error era will end in treating people suffering from depression
Very small molecules miR-1202 are hard to find in the brains of those people who are suffering from depression. These molecules actually help the brains fight depression and lack of them actually causes depression.

This is going to help many people get right treatment. This will also help physicians in finding people who may be cured when treated by antidepressant medication.

depression_2Dr Gustavo Turecki, one of the lead authors of the report say, “Using samples from the Douglas Bell-Canada Brain Bank, we examined brain tissues from individuals who were depressed and compared them with brain tissues from psychiatrically healthy individuals”. Dr Gustavo Turecki is a psychiatrist at the Douglas and professor in the Faculty of Medicine, Department of Psychiatry at McGill. The study has been jointly conducted by scientists at McGill University and the Douglas Institute

Researchers are of the opinion that depression caused disability in many cases and notwithstanding the fact that there are ready treatments for the problem, finding right medication is the most important problem.

They say that physicians make numerous mistakes while treating such patients and many a times aggravate the problem. But the problem is going to be solved in the days to come. Turecki says, “We identified this molecule, a microRNA known as miR-1202, only found in humans and primates and discovered that it regulates an important receptor of the neurotransmitter glutamate”.

While detailing his finding further Turecki further says, “In our clinical trials with living depressed individuals treated with citalopram, a commonly prescribed antidepressant, we found lower levels in depressed individuals compared to the non-depressed individuals before treatment…Clearly, microRNA miR-1202 increased as the treatment worked and individuals no longer felt depressed”. This is a huge development and will help millions of people suffering from depression.

Infosys team discovers solution to study bones

BANGALORE: It's a meeting of dissimilar subjects: principles of mechanical engineering are being used to understanding bone density and fracture risk.

A team of engineers from Infosys Technologies, Bangalore, has developed a solution using computer-assisted design and finite element analysis (FEA) tools to study mechanics of vertebrae, taking into account various factors such as shape, density distribution of cortical and cancellous bone.

The team comprising Dattatraya Parle, principal consultant, and Anirudha Ambulgekar, engineering analyst, from Infosys Engineering Services unit, in collaboration with medical experts, used MSC multi-disciplinary simulation solutions to enable doctors to study bones in a detailed and non-invasive manner. This, the team said, will help diagnose osteoporosis and accurately quantify fracture risk.

Last week, for the second time in a row, the team walked away as the winner of the prestigious 2014 Simulating Reality contest for their 'Osteoporosis solution'. In 2013, an Infosys team had won the Simulating Reality contest for its 3D model of the human heart, that helps medical professionals and scientists improve their understanding of the complexities of human heart disorders.

Currently, doctors estimate bone fracture risk using various methods such as physical examination of CT scans or X-rays and other physiological parameters such as gender, age and weight. "All these diagnostic methods are qualitative and may not take into account geometric and mechanical factors of vertebrae such as shape, cortical bone thickness, density distribution of cortical/cancellous bone, material properties of bone tissue etc. Our invention presents a solution for osteoporosis vertebra to quantitatively assess the fracture risk of vertebrae. Osteoporosis is a bone disease that is characterized by a decrease in bone density that reduces bone strength and increases risk of bone fracture. This solution brings together some of the best practices adopted in mechanical engineering industry to bio-medical industry," said Dr Ravi Kumar GVV, industry principal and head, Advanced Engineering Group, Infosys.

Though computational techniques have already been used in biomedical engineering, the current challenge involves the application of advanced biomedical simulations to clinical medicine and to the study of biological systems at different levels such as cell, tissue and organ. By 2015, around 15% of Indians may be osteoporotic due to increasing longevity of the Indian population. "This is what motivated the Infosys team to develop the current innovative solution for osteoporosis," he said.

The Infosys team worked on the solution for about three months, in collaboration with a radiologist. Initially, state-of-the-art practices and methodologies in osteoporosis were studied. CT scan images of osteoporotic patient vertebrae were used to generate a patient-specific 3D model containing the exact shape and size of their porosity. The 3D model was calibrated to actual dimensions prior to analysis for fracture risk.

A typical case of a person sitting erect where 1000 N compressive force in the lumbar spine is used for stress analysis. The computed compressive vertebra stresses are used to assess patient-specific fracture risk factor.

BEST TREATMENT POSSIBLE

With this new solution from Infosys, doctors can precisely determine the pathophysiology of the pain due to osteoporosis in individual cases. This will help us select the appropriate treatment option for each patient.

Dr Ketan Gaikwad | radiologist, Mumbai

Our engineering capabilities for the life sciences industry focus not only on innovation but also on improving existing medical procedures and processes. This breakthrough in reimagining osteoporosis diagnosis and treatment provides medical practitioners with a new, comprehensive and non-invasive way to examine individual bones and skeletal structure, and determine the best course of action.

Sudip Singh | vice-president and global head, engineering services, Infosys